FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226164037> ?p ?o ?g. }

• W4226164037 endingPage "131" @default.
• W4226164037 startingPage "131" @default.
• W4226164037 abstract "Sir, With reference to the therapy letter, “Successful treatment of acquired perforating dermatosis with colchicine” by Gil et al.,[1] we read with great interest the successful management of a difficult to treat condition. The authors reported a patient of acquired perforating dermatosis (APD) without any underlying comorbidity, who had no response to 1 month of high potency topical corticosteroids, but responded to addition of colchicine 1 mg twice daily (i.e., 2mg/day). The lesions improved rapidly, with significant reduction of pruritus, and resolution of lesions with residual post-inflammatory hyperpigmentation after 2 months of treatment. We wish to inform that we had also reported appreciable response to colchicine.[2] Our patient had unresponsive APD but with comorbidities in the form of type 2 diabetes mellitus and chronic kidney disease.[2] A rapid response was seen within 4 weeks, both in terms of reduction in itching and flattening of lesions. However, we had used a lower dose of colchicine (1 mg/day) in view of the underlying renal disease and succeeded. As patients with APD often have comorbidities and renal compromise,[3] we wish to highlight that even lower doses of colchicine may be effective. The possible mechanisms of action of colchicine have been well elucidated by Gil et al.[1] It includes downregulation of multiple inflammatory pathways, inhibition of microtubule formation, antifibrotic properties via inhibition of fibronectin and transforming growth factor-β1, and interference with leukocyte migration, adhesion, and degranulation.[45] It is a useful drug in the therapeutic armamentarium for many neutrophilic dermatoses.[4] Also, low dose colchicine has been found to be efficacious in treating pyoderma gangrenosum.[6] However, it should be kept in mind that the most common side effects which include nausea, vomiting, and diarrhea can be severe at times, even at recommended doses leading to drug discontinuation.[4] In addition to this, the uncommon side effects can be quite serious and life threatening at times like arrhythmias and bone marrow suppression, hence it may not be recommended as first-line therapy in all cases. Additional points of interest in the report by Gil et al. include the unilaterality of lesions, presence of larger ulcerated plaques with a necrotic dirty-looking floor, and a central eschar rather than a keratotic plug in most of the lesions shown.[1] We wonder if there were other pathologies at play in their case, including infectious causes. In view of the dramatic response to therapy seen with the above reports,[12] we would like to suggest that colchicine could be an effective treatment option in the management of a difficult dermatosis like APD. Low dose (1mg/day) may be considered as a starting dose, especially in patients with underlying renal disease and dose escalation may be considered slowly. APD is not an uncommon dermatosis, and more reports in this direction could help decide optimum treatment regimes. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4226164037 created "2022-05-05" @default.
• W4226164037 creator A5006233682 @default.
• W4226164037 creator A5016728667 @default.
• W4226164037 date "2022-01-01" @default.
• W4226164037 modified "2023-10-14" @default.
• W4226164037 title "Treatment of acquired perforating dermatosis with colchicine" @default.
• W4226164037 cites W1153335416 @default.
• W4226164037 cites W2079302207 @default.
• W4226164037 cites W3089887667 @default.
• W4226164037 cites W3095088349 @default.
• W4226164037 cites W3097177007 @default.
• W4226164037 cites W3131166464 @default.
• W4226164037 doi "https://doi.org/10.4103/idoj.idoj_163_21" @default.
• W4226164037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35198486" @default.
• W4226164037 hasPublicationYear "2022" @default.
• W4226164037 type Work @default.
• W4226164037 citedByCount "1" @default.
• W4226164037 countsByYear W42261640372023 @default.
• W4226164037 crossrefType "journal-article" @default.
• W4226164037 hasAuthorship W4226164037A5006233682 @default.
• W4226164037 hasAuthorship W4226164037A5016728667 @default.
• W4226164037 hasBestOaLocation W42261640371 @default.
• W4226164037 hasConcept C126322002 @default.
• W4226164037 hasConcept C141071460 @default.
• W4226164037 hasConcept C16005928 @default.
• W4226164037 hasConcept C2776636253 @default.
• W4226164037 hasConcept C71924100 @default.
• W4226164037 hasConceptScore W4226164037C126322002 @default.
• W4226164037 hasConceptScore W4226164037C141071460 @default.
• W4226164037 hasConceptScore W4226164037C16005928 @default.
• W4226164037 hasConceptScore W4226164037C2776636253 @default.
• W4226164037 hasConceptScore W4226164037C71924100 @default.
• W4226164037 hasIssue "1" @default.
• W4226164037 hasLocation W42261640371 @default.
• W4226164037 hasLocation W42261640372 @default.
• W4226164037 hasLocation W42261640373 @default.
• W4226164037 hasOpenAccess W4226164037 @default.
• W4226164037 hasPrimaryLocation W42261640371 @default.
• W4226164037 hasRelatedWork W1586374228 @default.
• W4226164037 hasRelatedWork W2003938723 @default.
• W4226164037 hasRelatedWork W2043656078 @default.
• W4226164037 hasRelatedWork W2047967234 @default.
• W4226164037 hasRelatedWork W2118496982 @default.
• W4226164037 hasRelatedWork W2364998975 @default.
• W4226164037 hasRelatedWork W2369162477 @default.
• W4226164037 hasRelatedWork W2439875401 @default.
• W4226164037 hasRelatedWork W4238867864 @default.
• W4226164037 hasRelatedWork W2525756941 @default.
• W4226164037 hasVolume "13" @default.
• W4226164037 isParatext "false" @default.
• W4226164037 isRetracted "false" @default.
• W4226164037 workType "article" @default.